[Short-Term Outcome of TAS-102 for Refractory Metastatic Colorectal Cancer].
We retrospectively analyzed 7 patients with refractory colorectal cancer treated with TAS-102 as salvage therapy. Subjects were 3 men and 4 women. The median age at initiation of TAS-102 was 71 years (range, 41-82 years). The number of target organs was 1 in 5 patients, 2 in 1 patient, and 3 in 1 patient. The median treatment courses were 2 courses (range, 1-6 courses). The reason for discontinuation was hematological toxicity in 1 patient, patients' wish in 3 patients, disease progression in 2 patients, and worsening of general condition in 1 patient. The median survival time since the first administration of TAS-102 was 9 months.
Dept. of Surgery, Tokyo Women's Medical University Medical Center East.
Kazuhiko
K
Yoshimatsu
Hajime
H
Yokomizo
Mao
M
Nakayama
Sachiyo
S
Okayama
Masaya
M
Satake
Akiko
A
Sakuma
Yuki
Y
Yano
Atsuo
A
Matsumoto
Takashi
T
Fujimoto
Takebumi
T
Usui
Kentaro
K
Yamaguchi
Shunichi
S
Shiozawa
Takeshi
T
Shimakawa
Takao
T
Katsube
Yoshihiko
Y
Naritaka
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011759:Pyrrolidines; D012189:Retrospective Studies; D016879:Salvage Therapy; D013941:Thymine; D016896:Treatment Outcome; D014271:Trifluridine / Q000627:therapeutic use*; D014498:Uracil / Q000031:analogs & derivatives* / Q000627:therapeutic use
D004338:Drug Combinations; D011759:Pyrrolidines; C000613803:trifluridine tipiracil drug combination; D014498:Uracil; D013941:Thymine; D014271:Trifluridine